Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Pancreatic Cancer
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
Early Closure of Phase 2 Trial on Checkpoint Inhibitors in Metastatic PDAC Due to Missed Efficacy End Point
Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.
Disrupted Glucose Metabolism Led to High Levels of DNA Damage in Pancreatic Tissue: Study
A new study has suggested disrupted glucose metabolism is linked to high levels of DNA damage in the pancreas, which may contribute to the acquisition of KRAS mutations and subsequent carcinogenesis.
Do Oncologists Change Practice Based on Inadequate Evidence?
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Higher Fasting Plasma Glucose May Up Pancreatic Cancer Risk
Continuous increase in risk of pancreatic cancer with elevating fasting glucose, even within normal range.
Novel Test Accurately Identifies Precancerous Pancreatic Cysts
Cyst classifier test is based on clinical and imaging features, genetic and biochemical markers.
Phase 3 Study Evaluating Novel Therapy for Pancreatic Cancer Discontinued
Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.
Solving the Obesity Paradox in Oncology
One potentially revolutionary hypothesis relates to the evolutionary processes involved in oncogenesis.
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
Next post in General Oncology
